The Annual Summit on Life Sciences IP Due Diligence to be held on November 14 and 15 in Boston, MA, is a one-of-a-kind, interactive forum where diligence experts discuss best practices and strategies for executing a proper IP due diligence analysis for incumbent portfolios and those of potential targets.
Tensions between public use, drug laws and regulators make IP around Cannabis a complex situation, explains Ludmila Kawakami and Ana Paula D. C. Couto of Di Blasi, Parente & Associados.
LSX World Congress USA brings life sciences investment and partnering to Boston.
As all sides prepare for a milestone case in the battle over rights to CRISPR/Cas9, LSIPR’s Rory O’Neill finds the CEO of ERS Genomics in a positive mood.
As lawyers and industry prepare for a possible no-deal Brexit, the uncertainty surrounding its impact is palpable, as LSIPR’s Saman Javed discovers.
LSIPR’s Sarah Morgan investigates the current state of play of M&A in the sector and predicts the next year of activity.
In-house counsel face daily challenges when managing and maintaining their IP portfolios. LSIPR asked two in-house counsel for the biggest challenges they face when managing and maintaining their IP portfolios. Here are the five things we learned.
While providing benefits to Mexico’s biologics system, the USMCA may also increase costs for citizens, argues Margarita Guerrero Gonzalez of Uhthoff, Gomez Vega & Uhthoff.
A tie-up between four leading pharmaceutical companies, the UK government and a health charity has created the world’s largest genetic research project. LSIPR’s Rory O’Neill looks at a new frontier for life sciences.
An intervention by Russia’s IP ombudsman seeks to solve the validity issue over secondary patents, but is it needed, asks Maxim Sobolev of Rouse.